{"DataElement":{"publicId":"12943971","version":"1","preferredName":"Prostate Carcinoma Magnetic Resonance Imaging M Stage Category","preferredDefinition":"Based on MRI, the extent of the distant metastasis for prostate carcinoma based on information obtained from the date of cancer diagnosis until the start of definitive treatment, or within four months (whichever is shorter).","longName":"PC_MRI_M_CAT","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"12939982","version":"1","preferredName":"Prostate Carcinoma Magnetic Resonance Imaging M Category","preferredDefinition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease._Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.:One criteria of the TNM staging system. M refers to the presence of metastasis.","longName":"12939967v1.00:2678077v1.00","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"12939967","version":"1","preferredName":"Prostate Carcinoma Magnetic Resonance Imaging","preferredDefinition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease._Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.","longName":"C4863:C16809","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Magnetic Resonance Imaging","conceptCode":"C16809","definition":"Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5CF8E94-9AEB-52F0-E053-731AD00A4FB7","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2678077","version":"1","preferredName":"M Stage","preferredDefinition":"One criteria of the TNM staging system.  M refers to the presence of metastasis.","longName":"C25727","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"M Category","conceptCode":"C25727","definition":"One criteria of the TNM staging system. M refers to the presence of metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3978B83D-5D9A-3E76-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-06","endDate":null,"createdBy":"UMLLOADER_COCANUT","dateCreated":"2007-09-06","modifiedBy":"ONEDATA","dateModified":"2007-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435021","version":"1","preferredName":"Diagnostic or Prognostic Factor","preferredDefinition":"Top level term which includes Biological Markers, Risk Factors, and Prognostic Factors.","longName":"C20047","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741C99A-9B70-231B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5CF959C-E2C1-53C0-E053-731AD00A8B25","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"KUMMEROA","dateModified":"2023-03-03","changeDescription":null,"administrativeNotes":"2023.3.3 Released per CCR review. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"12939846","version":"1","preferredName":"Prostate Carcinoma Magnetic Resonance Imaging M Category","preferredDefinition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease._Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders._One criteria of the TNM staging system. M refers to the presence of metastasis._A grouping of items based on some commonality or by user defined characteristics.","longName":"PC_MRI_M_CAT","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"45","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"M0","valueDescription":null,"ValueMeaning":{"publicId":"3201564","version":"1","preferredName":"M0 Stage Finding","longName":"3201564","preferredDefinition":"A distant metastasis TNM finding indicating that there is no evidence of distant metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"M0 TNM Finding","conceptCode":"C48699","definition":"A distant metastasis TNM finding indicating that there is no evidence of distant metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E24E347-9E82-3835-E040-BB89AD4379CD","latestVersionIndicator":"Yes","beginDate":"2011-03-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-03-10","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D03F25-56FC-77ED-E053-731AD00A6871","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"},{"value":"M1a","valueDescription":null,"ValueMeaning":{"publicId":"3201566","version":"1","preferredName":"M1a Stage Finding","longName":"3201566","preferredDefinition":"A TNM finding indicating the spread of cancer to distant anatomic sites.  The definition of M1a TNM finding depends on the specific type of cancer that it refers to; for example, for colorectal cancer it refers to metastasis confined to one organ or site (e.g., liver, lung, ovary, nonregional node); for prostate cancer it refers to metastasis to non-regional lymph node(s); for bone cancer it refers to metastasis to the lung.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"M1a TNM Finding","conceptCode":"C48701","definition":"A TNM finding indicating the spread of cancer to distant anatomic sites.  The definition of M1a TNM finding depends on the specific type of cancer that it refers to; for example, for colorectal cancer it refers to metastasis confined to one organ or site (e.g., liver, lung, ovary, nonregional node); for prostate cancer it refers to metastasis to non-regional lymph node(s); for bone cancer it refers to metastasis to the lung.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E24E347-9ECA-3835-E040-BB89AD4379CD","latestVersionIndicator":"Yes","beginDate":"2011-03-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-03-10","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D03F25-56FD-77ED-E053-731AD00A6871","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"},{"value":"M1b","valueDescription":null,"ValueMeaning":{"publicId":"3201567","version":"1","preferredName":"M1b Stage Finding","longName":"3201567","preferredDefinition":"A TNM finding indicating the spread of cancer to distant anatomic sites.  The definition of M1b TNM finding depends on the specific type of cancer that it refers to; for example, for colorectal cancer it refers to metastases in more than one organ/site or the peritoneum; for prostate cancer it refers to metastasis to bone(s); for bone cancer it refers to metastasis to distant sites other than lung.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"M1b TNM Finding","conceptCode":"C48702","definition":"A TNM finding indicating the spread of cancer to distant anatomic sites.  The definition of M1b TNM finding depends on the specific type of cancer that it refers to; for example, for colorectal cancer it refers to metastases in more than one organ/site or the peritoneum; for prostate cancer it refers to metastasis to bone(s); for bone cancer it refers to metastasis to distant sites other than lung.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E24E347-9EEF-3835-E040-BB89AD4379CD","latestVersionIndicator":"Yes","beginDate":"2011-03-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-03-10","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D03F25-56FE-77ED-E053-731AD00A6871","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"},{"value":"M1c","valueDescription":null,"ValueMeaning":{"publicId":"3201568","version":"1","preferredName":"M1c Stage Finding","longName":"3201568","preferredDefinition":"A TNM finding indicating the spread of cancer to distant anatomic sites.  The definition of M1c TNM finding depends on the specific type of cancer that it refers to; for example, for prostate cancer it refers to metastasis to anatomic site(s) other than bone, with or without bone disease; for retinoblastoma it refers to central nervous system metastasis; for melanoma of the uvea it refers to distant metastasis, with the largest diameter of the largest metastasis measuring 8.0 cm or more.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"M1c TNM Finding","conceptCode":"C48703","definition":"A TNM finding indicating the spread of cancer to distant anatomic sites.  The definition of M1c TNM finding depends on the specific type of cancer that it refers to; for example, for prostate cancer it refers to metastasis to anatomic site(s) other than bone, with or without bone disease; for retinoblastoma it refers to central nervous system metastasis; for melanoma of the uvea it refers to distant metastasis, with the largest diameter of the largest metastasis measuring 8.0 cm or more.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E24E347-9F14-3835-E040-BB89AD4379CD","latestVersionIndicator":"Yes","beginDate":"2011-03-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-03-10","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D03F25-56FF-77ED-E053-731AD00A6871","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"},{"value":"Other","valueDescription":null,"ValueMeaning":{"publicId":"6431768","version":"1","preferredName":"Other","longName":"6431768v1.00","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"762A692A-EEF7-29A1-E053-F662850A9EA9","latestVersionIndicator":"Yes","beginDate":"2018-09-18","endDate":null,"createdBy":"WINCHC","dateCreated":"2018-09-18","modifiedBy":"GDEEN","dateModified":"2024-01-22","changeDescription":null,"administrativeNotes":"2023.2.1 Alt VM added per ticket request CADSR0001995. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D03F25-5700-77ED-E053-731AD00A6871","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"12939845","version":"1","preferredName":"Prostate Carcinoma Magnetic Resonance Imaging M Category Category","preferredDefinition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease._Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders._One criteria of the TNM staging system. M refers to the presence of metastasis._A grouping of items based on some commonality or by user defined characteristics.","longName":"12939845v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Magnetic Resonance Imaging","conceptCode":"C16809","definition":"Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"M Category","conceptCode":"C25727","definition":"One criteria of the TNM staging system. M refers to the presence of metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5C9F7DC-ACE2-6510-E053-731AD00A15B5","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5C9F7DC-ACE9-6510-E053-731AD00A15B5","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"KUMMEROA","dateModified":"2023-03-03","changeDescription":null,"administrativeNotes":"2023.3.3 Released per CCR review. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"MRI (M-stage)","type":"Preferred Question Text","description":"MRI (M-stage)","url":null,"context":"CCR"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5D11947-7F4C-0A77-E053-731AD00A68A3","latestVersionIndicator":"Yes","beginDate":"2023-03-01","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-03-01","modifiedBy":"KUMMEROA","dateModified":"2023-03-03","changeDescription":null,"administrativeNotes":"2023.3.3 Released per CCR review. ak","unresolvedIssues":null,"deletedIndicator":"No"}}